Literature DB >> 27717780

HIV-infection and psychiatric illnesses - A double edged sword that threatens the vision of a contained epidemic: The Greater Stockholm HIV Cohort Study.

Amadou Jallow1, Gunnar Ljunggren2, Per Wändell3, Lars Wahlström4, Axel C Carlsson5.   

Abstract

CONTEXT: The Greater Stockholm HIV Cohort Study is an initiative to provide longitudinal information regarding the health of people living with HIV.
OBJECTIVE: Our aim was to explore the prevalence of HIV and its association with psychiatric co-morbidities. DESIGN, SETTING AND PARTICIPANTS: All patients with a recorded diagnosis of HIV (any position of the ICD-10 codes B20-B24) were identified during the period 2007-2014 and related to the total population in Stockholm by January 1, 2015, N = 2.21 million. The age at diagnosis, gender, and first occurrence of an HIV diagnosis was recorded. Analyses were done by age and gender. Prevalence of psychiatric co-morbidities amongst HIV patients were recorded. MAIN OUTCOME MEASURES: Age-adjusted odds ratios with 95% confidence intervals were calculated with logistic regression for prevalent psychiatric co-morbidities in HIV infected individuals compared to the prevalence in the general population.
RESULTS: The total prevalence of HIV was 0.16%; females 0.10% (n = 1134) and males 0.21% (n = 2448). HIV-infected people were more frequently diagnosed with psychiatric illnesses and drug abuse. In females and males with HIV-diagnosis respectively, drug dependence disorder was 7.5 (7.76% vs 1.04%) and 5.1 (10.17% vs 1.98%) times higher, psychotic disorders were 6.3 (2.65% vs 0.42%) and 2.9 (1.43% vs 0.49%) times higher, bipolar disorder was 2.5 (1.41% vs 0.57%) and 3 (1.02% vs 0.34%) times higher, depression diagnosis was 1.5 (8.47% vs 5.82%) and 3.4 (10.17% vs 2.97%) higher, trauma-related disorder was 1.5 (6.00% vs 4.10%) respectively 2.9 (4.45% vs 1.56%) times higher, anxiety disorder was 1.2 (6.88% vs 5.72%) and 2.2 (6.54% vs 2.93%) times higher than in their non-infected peers.
CONCLUSION: Despite effective ART, many individuals with HIV have an impaired mental health and a history of drug abuse that may threaten the vision of a contained epidemic.
Copyright © 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Administrative databases; Anxiety disorders; Bipolar disorders; Depression; Drug dependence disorders; Epidemiology; Gender; General population; Psychotic disorders; Trauma-related disorders

Mesh:

Year:  2016        PMID: 27717780     DOI: 10.1016/j.jinf.2016.09.009

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  12 in total

1.  Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS.

Authors:  Sarah Tymchuk; Daniela Gomez; Noshin Koenig; M John Gill; Esther Fujiwara; Christopher Power
Journal:  Can J Psychiatry       Date:  2017-12-11       Impact factor: 4.356

Review 2.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

3.  Health Care Consumption, Psychiatric Diagnoses, and Pharmacotherapy 1 and 2 Years Before and After Newly Diagnosed HIV: A Case-Control Study Nested in The Greater Stockholm HIV Cohort Study.

Authors:  Per Wändell; Gunnar Ljunggren; Amadou Jallow; Lars Wahlström; Axel C Carlsson
Journal:  Psychosom Med       Date:  2022-08-20       Impact factor: 3.864

Review 4.  The role of human dopamine transporter in NeuroAIDS.

Authors:  Jun Zhu; Subramaniam Ananthan; Chang-Guo Zhan
Journal:  Pharmacol Ther       Date:  2017-10-05       Impact factor: 12.310

5.  Beyond the HIV Care Continuum and Viral Suppression: Broadening the Scope of Quality Metrics for Total HIV Patient Care.

Authors:  Michael A Horberg; Julia M Certa; Kevin B Rubenstein; Leo B Hurley; Derek D Satre; Peter M Kadlecik; Michael J Silverberg
Journal:  AIDS Patient Care STDS       Date:  2020-11       Impact factor: 5.078

6.  Identifying causes of persistent HIV viremia in adult patients at an academic medical center.

Authors:  Julie Steinbrink; Hannah Imlay; Krishna Rao; James Riddell
Journal:  SAGE Open Med       Date:  2019-05-14

7.  S-Equol mitigates motivational deficits and dysregulation associated with HIV-1.

Authors:  Kristen A McLaurin; Sarah J Bertrand; Jessica M Illenberger; Steven B Harrod; Charles F Mactutus; Rosemarie M Booze
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

8.  The Reliability and Validity of The Turkish Form of Berger HIV Stigma Scale.

Authors:  Mevhibe İrem Yildiz; Koray Başar; Özge Karadağ Çaman; Ahmet Çağkan Inkaya
Journal:  Noro Psikiyatr Ars       Date:  2021-11-15       Impact factor: 1.339

9.  Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy.

Authors:  Monica M Diaz; John R Keltner; Alan N Simmons; Donald Franklin; Raeanne C Moore; David Clifford; Ann C Collier; Benjamin B Gelman; Ph D Christina Marra; J Allen McCutchan; Susan Morgello; Ned Sacktor; Brookie Best; Christine Fennema Notestine; Sara Gianella Weibel; Igor Grant; Thomas D Marcotte; Florin Vaida; Scott Letendre; Robert Heaton; Ronald J Ellis
Journal:  Pain Med       Date:  2021-08-06       Impact factor: 3.750

10.  Feasibility and Acceptability of a Program to Promote Positive Affect, Well-Being and Gender Empowerment in Black Women Living with HIV.

Authors:  S M Bassett; L R Brody; D C Jack; K M Weber; M H Cohen; T M Clark; S K Dale; J T Moskowitz
Journal:  AIDS Behav       Date:  2021-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.